Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Cambridge Cognition Holdings ( (GB:COG) ).
Cambridge Cognition reported a strong rebound in commercial momentum for 2025, with new sales orders surging 73% to £12.8m and the year-end order book rising 25% to £16.9m, even as reported revenues declined 10% to about £9.4m due to a weaker prior-year order book. The company kept its adjusted EBITDA loss and revenue broadly in line with revised market expectations, improved its balance sheet through tighter cost control, reduced borrowings, and an August equity placing, ending the year with net cash of £0.2m. Strategically, Cambridge Cognition has expanded beyond its traditional research and pharma focus into professional healthcare and consumer health and wellness, launching its CANTAB Pathway™ clinical assessment platform and securing a first major pilot with a large European private healthcare group that could scale to a pan-European roll-out. Management enters 2026 highlighting a stronger sales pipeline, a growing presence in consumer cognitive health, and an enlarged order book that is expected to support higher revenue, earnings, and cash generation in the year ahead.
The most recent analyst rating on (GB:COG) stock is a Sell with a £27.00 price target. To see the full list of analyst forecasts on Cambridge Cognition Holdings stock, see the GB:COG Stock Forecast page.
Spark’s Take on GB:COG Stock
According to Spark, TipRanks’ AI Analyst, GB:COG is a Neutral.
Cambridge Cognition Holdings faces significant financial and operational challenges, with declining revenue and negative profitability metrics. Technical indicators suggest bearish momentum, and valuation metrics are unattractive due to ongoing losses. However, recent corporate events, including strategic board appointments and share capital expansion, provide a positive outlook for future growth and market presence.
To see Spark’s full report on GB:COG stock, click here.
More about Cambridge Cognition Holdings
Cambridge Cognition Holdings is a neuroscience technology company specialising in digital cognitive assessments that support scientific research, pharmaceutical clinical trials, and patient care. Leveraging curated data and proprietary touch-screen and voice-based tasks, the company targets four key markets: clinical studies for new pharmaceuticals, academic research into central nervous system disorders, healthcare settings where clinicians assess and manage cognitive function, and the consumer health and wellness segment, where individuals can monitor their brain health.
Average Trading Volume: 16,553
Technical Sentiment Signal: Strong Sell
Current Market Cap: £13.04M
Find detailed analytics on COG stock on TipRanks’ Stock Analysis page.